About: Regulatory T cells as adjuvant target for enhancing the viral disease vaccine efficacy

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Regulatory T cells as adjuvant target for enhancing the viral disease vaccine efficacy Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Regulatory T cells as adjuvant target for enhancing the viral disease vaccine efficacy
Creator	Bayry, Jagadeesh
Source	Medline; PMC
abstract	CD4(+)CD25(+)FoxP3(+) regulatory T cells (Tregs) are critical for immune homeostasis and tolerance. However, because of their capacity to suppress antigen presenting cells (APC), T and B cells, Tregs could also inhibit protective immune responses to viruses and vaccines. Several viruses have been shown to exploit Tregs to evade immune response. By modulating APC and in particular by weakening the functions of dendritic cells such as their ability to secrete polarizing cytokines and expression of co-stimulatory molecules, viruses could support differentiation and expansion of Tregs. Of note, as a proof of concept, depletion of Tregs significantly enhanced the protective immune response to viruses and vaccines suggesting that Tregs are viable targets to enhance immunogenicity of vaccines. As Treg depletion or inhibition of their functions could lead to deleterious autoimmune and inflammatory disorders, any Treg-based approach for vaccination should not aim at depletion of Tregs and inhibition of their functions should be transient. Recent studies have targeted the interaction between CCR4 expressed on Tregs and its ligands CCL22 and CCL17 to inhibit transiently the recruitment of Tregs at the site of immunization. Importantly, use of CCR4 antagonists as ‘molecular adjuvants’ in vivo in experimental models, amplified cellular and humoral immune responses when injected in combination with various vaccine antigens. The significant adjuvant activity observed in diverse models without noticeable side effects provided strong evidence that CCR4 is a sustainable target for rational adjuvant design.
has issue date	2013-11-29(xsd:dateTime)
bibo:doi	10.1007/s13337-013-0187-3
bibo:pmid	24426307
has license	green-oa
sha1sum (hex)	35292b492d52cd4d91967a43338fb6ab4347352a
schema:url	https://doi.org/10.1007/s13337-013-0187-3
resource representing a document's title	Regulatory T cells as adjuvant target for enhancing the viral disease vaccine efficacy
has PubMed Central identifier	PMC3889236
has PubMed identifier	24426307
schema:publication	VirusDisease
resource representing a document's body	covid:35292b492d52cd4d91967a43338fb6ab4347352a#body_text
is schema:about of	named entity 'Regulatory T cells' named entity 'viral disease' named entity 'VIRAL DISEASE' named entity 'ADJUVANT' named entity 'VACCINE EFFICACY' named entity 'ENHANCING' named entity 'TARGET' named entity 'REGULATORY T CELLS' named entity 'viral disease' named entity 'antigens' named entity 'monoclonal antibodies' named entity 'toll-like receptor 4' named entity 'TLRs' named entity 'immunization' named entity 'Tregs' named entity 'STAT4' named entity 'effector T cells' named entity 'Tregs' named entity 'TLR4' named entity 'protein vaccines' named entity 'IFN' named entity 'Small molecule' named entity 'FoxP3' named entity 'immune responses' named entity 'Tregs' named entity 'antigens' named entity 'viruses' named entity 'CD4' named entity 'immunosuppressive' named entity 'immune tolerance' named entity 'tissue damage' named entity 'CD8' named entity 'Tregs' named entity 'vaccine' named entity 'influenza' named entity 'Cellular immunity' named entity 'influenza' named entity 'granulocyte' named entity 'IL-1b' named entity 'Tregs' named entity 'CD4' named entity 'self-replicating' named entity 'CCR4' named entity 'immune responses' named entity 'vaccine' named entity 'antigens' named entity 'adhesion molecule' named entity 'Tregs' named entity 'CTLA-4' named entity 'MHC class II' named entity 'co-stimulatory molecules' named entity 'IL-13' named entity 'inflammatory cytokines' named entity 'humoral' named entity 'Tregs' named entity 'CCR4' named entity 'IL-17A' named entity 'adjuvants' named entity 'CD25' named entity 'Th17 cells' named entity 'immunization' named entity 'Tregs' named entity 'airway' named entity 'homeostasis' named entity 'foot and mouth disease' named entity 'interleukin-2' named entity 'induced Tregs' named entity 'adjuvants' named entity 'Tregs' named entity 'CCL22' named entity 'CD8' named entity 'antibody' named entity 'CCR4' named entity 'CD4' named entity 'PRRs' named entity 'effector cell' named entity 'cell-mediated' named entity 'CCR4' named entity 'cross-presentation' named entity 'CD4' named entity 'cytokines'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software